Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Creatine Treatment in Psychiatric Disorders
This study is currently recruiting participants.
Verified by Beersheva Mental Health Center, October 2005
Sponsors and Collaborators: Beersheva Mental Health Center
National Alliance for Research on Schizophrenia and Depression
Information provided by: Beersheva Mental Health Center
ClinicalTrials.gov Identifier: NCT00140192
  Purpose

Creatine plays a pivotal role in brain energy homeostasis. Creatine supplementation is widely used in enhancing sports performance, and has been tried in the treatment of neurological, neuromuscular and atherosclerotic disease with a paucity of side effects.

Dechent et al (1999) studied the effect of oral creatine supplementation for 4 wk demonstrating a statistically significant increase of mean concentration of total creatine across brain regions. These findings suggest the possibility of using oral creatine supplementation to modify brain high-energy phosphate metabolism in subjects with various brain disorders, including schizophrenia and major depression. Recently, Rae et al (2003) reported that creatine supplementation for 6 weeks had a significant positive effect on both working memory and Raven matrices. Several independent lines of evidence suggest the possible involvement of altered cerebral energy metabolism in schizophrenia.

We are performing a double blind cross-over study of creatine in schizophrenia.

Forty patients will be treated with creatine for 3 months in a double-blind crossover design. Rating scales will include scales for assessing negative and positive symptoms of schizophrenia, clinical global impressions scale, scales for side–effects and a cognitive battery

Creatine effects on brain energy metabolism and its possible cognitive enhancing properties raise the possibility of developing a new therapeutic strategy in schizophrenia focusing on treating metabolic hypoactive brain areas including frontal regions.


Condition Intervention Phase
Schizophrenia
Drug: creatine
Phase III

MedlinePlus related topics: Mental Health Schizophrenia
Drug Information available for: Creatine
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title: Creatine as a New Treatment for Schizophrenia:A Double-Blind Trial

Further study details as provided by Beersheva Mental Health Center:

Primary Outcome Measures:
  • Positive and Negative Syndrome Scale
  • Clincal Global Impression

Estimated Enrollment: 40
Study Start Date: September 2004
Estimated Study Completion Date: September 2006
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age 18-60
  • physically healthy
  • at least 2 years of illness in a stable condition
  • presenting negative and cognitive symptoms

Exclusion Criteria:

  • drug or alcohol abuse
  • clinically significant medical condition
  • laboratory abnormality
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00140192

Locations
Israel
Beersheva Mental Health Center Recruiting
Beersheva, Israel
Contact: Alex Kaptsan, MD     972-8-6401602     akaptsan@bgu.ac.il    
Contact: RH Belmaker, MD     972-8-6401602     belmaker@bgu.ac.il    
Sub-Investigator: Alex Kaptsan, MD            
Principal Investigator: Joseph Levine, MD            
Sponsors and Collaborators
Beersheva Mental Health Center
National Alliance for Research on Schizophrenia and Depression
Investigators
Study Director: RH Belmaker, MD Ben Gurion University of the Negev + Beersheva Mental Health Center
  More Information

Publications indexed to this study:
Study ID Numbers: BMHC-3835
Study First Received: August 31, 2005
Last Updated: October 9, 2006
ClinicalTrials.gov Identifier: NCT00140192  
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Beersheva Mental Health Center:
creatine metabolism
schizophrenia
energy metabolism

Study placed in the following topic categories:
Schizophrenia
Mental Disorders
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on January 13, 2009